Navigation Links
Frost & Sullivan: Expiration of Patents for Leading Drugs to Bolster the Oral Solid Drug Dosage Excipients Market in North America

MOUNTAIN VIEW, Calif., June 25, 2013 /PRNewswire/ -- Best-selling drugs with a combined worth of $73.85 billion that include Lipitor, Actos and Plavix are expected to lose patent protection in the United States by 2017. As a result, an influx of generic manufacturers and an increased volume of new drugs is expected in the market, thus sustaining the demand for oral solid drug dosage excipients in North America. These inert substances serve as vehicles for active ingredients in drugs and include binders and fillers, disintegrants, coatings, flavors, colors, sweeteners, glidants, adhesives and lubricants.

New analysis from Frost & Sullivan (, Analysis of the North American Oral Solid Drug Dosage Excipients Market, finds that the market earned revenue of $1.19 billion in 2012 and estimates this to reach $1.70 billion in 2019 at a compound annual growth rate of 5.4 percent.

If you are interested in more information on this research, please send an e-mail to Jeannette Garcia, Corporate Communications, at, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.

"The need to improve drug manufacturing processes and the quality of drug formulations has led to the production of multi-functional excipients with better manufacturing accuracy and purity," said Frost & Sullivan Chemicals, Materials and Food Industry Analyst Dr. Nandhini Rajagopal, Ph.D. "The upcoming cost-effective tablet processing method, in particular, will require excipients with excellent functionalities and improved physical and chemical properties."

Cost containment efforts by the government and healthcare providers have further escalated the import of generic drugs to the United States, resulting in price erosion and reduced margins for domestic excipient vendors.

Manufacturers can overcome price restraints by shifting their production facilities to less costly regions such as Asia. Also, due to stringent regulations and intense competition, it is also essential for companies to invest in research and development to benefit in the long run.

"Excipient suppliers in North America have focused on high-margin segments, such as coating polymers, co-processed excipients, coating systems and super disintegrants to boost their profit. However, the expensive nature of drugs and low-cost competition from emerging markets may restrict the overall drug manufacturing market in the country," added Frost & Sullivan Vice President of Chemicals, Materials and Food Growth Consulting Shomik Majumdar.

Analysis of the North American Oral Solid Drug Dosage Excipients Market is part of the Chemicals & Materials Growth Partnership Service program. Frost & Sullivan's related research services cover the Chinese pharmaceutical excipient market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Analysis of the North American Oral Solid Drug Dosage Excipients Market

Contact: Jeannette Garcia
Corporate Communications – North America
P: 210.477.8427
Twitter: @Frost_Sullivan
Facebook: FrostandSullivan 
Linkedin: Future of Chemicals- A Frost & Sullivan Forum 

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
2. Frost & Sullivan: mHealth Serves as the Catalyst for Healthcares Evolution
3. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
4. Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
5. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Development of New Technologies Spurs Molecular Diagnostic Test Volumes in Asia-Pacific, Finds Frost & Sullivan
8. Frost & Sullivan Market Share Leadership Award Highlights Acuo Technologies Accomplishments in Enterprise Imaging Informatics
9. Mega Trends Foster Investment, Innovation and Expansion in Latin America, Finds Frost & Sullivan
10. Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
11. Frost & Sullivan: Opportunities for Electronics Manufacturing Services in Medical Industry Increasing
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):